Roche and NHS England hail pricing deal on MS drug Ocrevus

Another pricing deal on high cost medicine. NHS England is claiming another successful negotiation with pharma after it agreed a lower price with Roche for its multiple sclerosis treatment Ocrevus. ... Roche says its trial data shows the drug is the

Orphan drugs market to soar to $224bn by 2024

The report warns the promise of innovative products such as Zolgensma and Lentiglobin “will only become reality if the innovation of drug companies is matched by innovation in the drug pricing ... Luxturna’s current list price is $425, 000 per eye,

Gottlieb signs off with flair – and pledge of further drug price commentary

This was based on Gottlieb’s bold approach to addressing unnecessary barriers to innovative medicines approvals, while at the same time tackling bottlenecks in generic drug approvals and pricing and competition ... This would once have been a radical

Trump budget targets rebates, out-of-pocket costs

Away from drug pricing, the budget includes an increase in funding for HIV programmes, a 12.6% drop in funding for the National Institutes of Health (NIH) which is likely to ... The budget would fundamentally upset the successful Medicare drug benefit

Vertex chief Jeffrey Leiden to weigh in on Orkambi inquiry

But that war has been waged since 2016, when England’s cost-effectiveness watchdog first rejected the £100, 000 drug citing that the price was “ unsupportable”.. ... That deal included the approval of Vertex’s next-generation CF treatment Symkevi

The Orkambi row explained

But the Orkambi row does stand out. One key factor is that back in 2013, Vertex managed to get a very favourable pricing deal for its first CF drug, Kalydeco. ... Canada also recently refused reimbursement and Spain is caught in a similar stand- off to

Deal Watch October 2018

The Health Secretary, Alex Azar, has promised more to come on “fixing” drug pricing and introducing transparency into drug prices, and in the present political climate that can only be good ... Endocyte’s lead clinical product is 177Lu‐PSMA‐617,

Trust me, I’m from pharma

However, controversies around drug pricing – fuelled by the unhelpful interventions of Martin Shkreli as the pin-up boy for big, bad pharma – have undermined progress and reinforced the view that the ... Individual companies are doing their bit too.

Patient outcomes in practice: delivering value that transforms lives

Providers, payers and manufacturers all have a role in achieving value, with increasing ethical pressure on drug pricing and resultant innovative, outcomes-based pricing models.

Drug pricing

Pfizer’s Emms takes up ABPI presidency

Emms is no stranger to these issues, having served on the ABPI board and taken part in the negotiations over the future of drug pricing in the UK. ... He has not been afraid to criticise the outcomes of these discussions too, saying in November that the

Bayer's Martin Hesse moves to Daiichi Sankyo Europe

Commenting on the environment in which he starts at Daiichi, Hesse said securing the company's profitability and competitiveness in the light of drug pricing interventions will a major challenge.

Precision medicine with precision management and precision pricing; ensuring affordability in the cell and gene therapy era

drug pricing?”. ... current barriers to progress in this area include perverse financial incentives, separation of hospital and drug budgets and inefficiencies within the system.

OPEN Health

drug pricing?”.

Pricing's Point Man

In the wake of the publication of the second edition of 'The Price of Global Health', Ed Schoonveld talks to William Looney. Pharm Exec Editor-in-Chief William Looney talks to Ed Schoonveld about the key policy and management issues around market

Turkey: Identifying the Growth Drivers

This sector is dominated by pro-innovative drug prescribing physicians as well as a patient population who is willing to pay for a higher “quality” healthcare. ... Overall, while the public sector is characterised today byaggressive drug pricing

Article: The Colombia Conundrum

drug pricing, as well as a streamlining of the essential drug list to remove some of the higher cost drugs. In a move to combat corruption, the EPS are set to ... This is exemplified by Sanofi’s 2012 acquisition of Genfar, which has resulted in the